Literature DB >> 8794351

The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta1 gene through an Egr-1 binding site.

Y D Yoo1, C J Chiou, K S Choi, Y Yi, S Michelson, S Kim, G S Hayward, S J Kim.   

Abstract

Increases in transforming growth factor beta1 (TGF-beta1) mRNA and biological activity in the early phase of human cytomegalovirus (CMV) infection in fibroblasts are paralleled by increased TGF-beta1-chloramphenicol acetyltransferase (CAT) reporter gene activity. To determine how CMV infection transactivates the TGF-beta1 promoter, we examined the effects of the cotransfected IE2 regulatory protein of human CMV on 5'-deleted TGF-beta1 promoter-CAT reporter genes in transient DNA transfection assays. Two upstream TGF-beta1 promoter regions each containing an Egr-1 consensus site were shown to be important for IE2-induced transactivation in a cell type that displayed greatly reduced nonspecific activity. Furthermore, transfer of an Egr-l site from between positions -125 and -98, but not point mutant versions of this site, to a heterologous promoter also conveyed IE2 responsiveness. Addition of an IE2 expression vector or use of the U373 A45 astrocytoma cell line expressing IE2 also produced synergistic stimulation of GAL4-Egr-l-mediated activation of a target promoter containing GAL4 binding sites. The 80-kDa IE2 protein present in A45 cells proved to selectively bind to glutathione S-transferase (GST)-Egr-1 beads. The results of in vitro protein binding assays also revealed that an intact in vitro-translated IE2 protein bound directly to the GST-Egr-1 fusion protein through the zinc finger domain of the Egr-1 protein and that this binding activity was abolished by deletion of parts of the zinc finger DNA-binding domain. Similarly, the Egr-1 protein was found to associate preferentially with a small region within the C-terminal half of the IE2 protein adjacent to the DNA-binding and dimerization domains that are important for both transactivation and downregulation. We conclude from these observations that IE2 may regulate transcription of the TGF-beta1 gene as well as other potential cellular targets by virtue of its ability to interact with the Egr-1 DNA-binding protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794351      PMCID: PMC190757     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1.

Authors:  A L Gashler; S Swaminathan; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

2.  UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression.

Authors:  M Winkler; S A Rice; T Stamminger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells.

Authors:  S J Kim; K Park; B B Rudkin; B R Dey; M B Sporn; A B Roberts
Journal:  J Biol Chem       Date:  1994-02-04       Impact factor: 5.157

4.  TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest.

Authors:  M E Ewen; H K Sluss; L L Whitehouse; D M Livingston
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

5.  Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1.

Authors:  S Michelson; J Alcami; S J Kim; D Danielpour; F Bachelerie; L Picard; C Bessia; C Paya; J L Virelizier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.

Authors:  B R Dey; V P Sukhatme; A B Roberts; M B Sporn; F J Rauscher; S J Kim
Journal:  Mol Endocrinol       Date:  1994-05

7.  Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.

Authors:  E Speir; R Modali; E S Huang; M B Leon; F Shawl; T Finkel; S E Epstein
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1.

Authors:  R M Stenberg; P R Witte; M F Stinski
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

9.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.

Authors:  C Hagemeier; R Caswell; G Hayhurst; J Sinclair; T Kouzarides
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

10.  The human cytomegalovirus 86K immediate early (IE) 2 protein requires the basic region of the TATA-box binding protein (TBP) for binding, and interacts with TBP and transcription factor TFIIB via regions of IE2 required for transcriptional regulation.

Authors:  R Caswell; C Hagemeier; C J Chiou; G Hayward; T Kouzarides; J Sinclair
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

View more
  42 in total

1.  Characterization of a human cytomegalovirus with phosphorylation site mutations in the immediate-early 2 protein.

Authors:  Julie A Heider; Yongjun Yu; Thomas Shenk; James C Alwine
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  TAF-like functions of human cytomegalovirus immediate-early proteins.

Authors:  D M Lukac; N Y Harel; N Tanese; J C Alwine
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Consensus on the role of human cytomegalovirus in glioblastoma.

Authors:  Kristine Dziurzynski; Susan M Chang; Amy B Heimberger; Robert F Kalejta; Stuart R McGregor Dallas; Martine Smit; Liliana Soroceanu; Charles S Cobbs
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

5.  Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.

Authors:  Kristine Dziurzynski; Jun Wei; Wei Qiao; Mustafa Aziz Hatiboglu; Ling-Yuan Kong; Adam Wu; Yongtao Wang; Daniel Cahill; Nicholas Levine; Sujit Prabhu; Ganesh Rao; Raymond Sawaya; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2011-04-13       Impact factor: 12.531

6.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein.

Authors:  Eung-Soo Hwang; Zhigang Zhang; Haobin Cai; David Y Huang; Shu-Mei Huong; Chang-Yong Cha; Eng-Shang Huang
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

8.  Analysis of splice variants of the immediate-early 1 region of human cytomegalovirus.

Authors:  Sita Awasthi; Jennifer A Isler; James C Alwine
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Phosphorylation of the human cytomegalovirus 86-kilodalton immediate-early protein IE2.

Authors:  N Y Harel; J C Alwine
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor-beta1 and increased collagen production.

Authors:  Takako Tabata; Hisaaki Kawakatsu; Ekaterina Maidji; Takao Sakai; Keiko Sakai; June Fang-Hoover; Motohiko Aiba; Dean Sheppard; Lenore Pereira
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.